CN106103422B - 异喹啉衍生物及其用途 - Google Patents

异喹啉衍生物及其用途 Download PDF

Info

Publication number
CN106103422B
CN106103422B CN201580015712.3A CN201580015712A CN106103422B CN 106103422 B CN106103422 B CN 106103422B CN 201580015712 A CN201580015712 A CN 201580015712A CN 106103422 B CN106103422 B CN 106103422B
Authority
CN
China
Prior art keywords
compound
alkyl
optionally substituted
group
pain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201580015712.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN106103422A (zh
Inventor
莱基·塔费塞
朴宰贤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Pharma LP
Original Assignee
Purdue Pharma LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Pharma LP filed Critical Purdue Pharma LP
Publication of CN106103422A publication Critical patent/CN106103422A/zh
Application granted granted Critical
Publication of CN106103422B publication Critical patent/CN106103422B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201580015712.3A 2014-02-12 2015-02-12 异喹啉衍生物及其用途 Expired - Fee Related CN106103422B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461939082P 2014-02-12 2014-02-12
US61/939,082 2014-02-12
PCT/US2015/015576 WO2015123398A1 (en) 2014-02-12 2015-02-12 Isoquinoline derivatives and use thereof

Publications (2)

Publication Number Publication Date
CN106103422A CN106103422A (zh) 2016-11-09
CN106103422B true CN106103422B (zh) 2020-09-18

Family

ID=53800620

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580015712.3A Expired - Fee Related CN106103422B (zh) 2014-02-12 2015-02-12 异喹啉衍生物及其用途

Country Status (8)

Country Link
US (2) US10738026B2 (enExample)
EP (1) EP3105217B1 (enExample)
JP (1) JP6556154B2 (enExample)
CN (1) CN106103422B (enExample)
AU (1) AU2015217185B2 (enExample)
CA (1) CA2939501C (enExample)
IL (1) IL247252B (enExample)
WO (1) WO2015123398A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10138207B2 (en) 2012-11-09 2018-11-27 Purdue Pharma, L.P. Benzomorphan analogs and the use thereof
US9120786B2 (en) 2013-03-04 2015-09-01 Purdue Pharma, L.P. Triazine carboxamides as sodium channel blockers
CA3082427A1 (en) 2013-03-15 2014-09-25 Purdue Pharma L.P. Carboxamide derivatives and use thereof
CA2922567A1 (en) 2013-08-26 2015-03-05 Purdue Pharma L.P. Azaspiro[4.5]decane derivatives and use thereof
US9828348B2 (en) 2013-11-08 2017-11-28 Purdue Pharma L.P. Benzimidazole derivatives and use thereof
JP6337124B2 (ja) 2013-12-23 2018-06-06 パーデュー、ファーマ、リミテッド、パートナーシップ インダゾール及びその使用
US9656962B2 (en) 2013-12-26 2017-05-23 Purdue Pharma L.P. Ring-contracted morphinans and the use thereof
WO2015097547A1 (en) 2013-12-26 2015-07-02 Purdue Pharma L.P. 10-substituted morphinan hydantoins
WO2015097548A1 (en) 2013-12-26 2015-07-02 Purdue Pharma L.P. 7-beta-alkyl analogs of orvinols
EP3087079B1 (en) 2013-12-26 2019-04-03 Purdue Pharma LP Opioid receptor modulating oxabicyclo[2.2.2]octane morphinans
WO2015099863A1 (en) 2013-12-27 2015-07-02 Purdue Pharma L.P. 6-substituted and 7-substituted morphinan analogs and the use thereof
JP6526023B2 (ja) 2014-01-24 2019-06-05 パーデュー、ファーマ、リミテッド、パートナーシップ ピリジン類及びピリミジン類並びにその使用
JP2017521373A (ja) 2014-05-27 2017-08-03 パーデュー、ファーマ、リミテッド、パートナーシップ スピロ環モルフィナン及びその使用
CA2951697A1 (en) 2014-06-13 2015-12-17 Purdue Pharma L.P. Azamophinan derivatives and use thereof
MA41125A (fr) 2014-12-05 2017-10-10 Purdue Pharma Lp Dérivés de 6.7-cyclomorphinane et leur utilisation
CN110325516A (zh) 2016-12-29 2019-10-11 米尼奥尔克斯治疗有限公司 杂芳基化合物和它们的用途
WO2018125716A1 (en) 2017-01-02 2018-07-05 Purdue Pharma L.P. Morphinan derivatives and use thereof
EP3589626B1 (en) * 2017-03-03 2024-06-12 National Taiwan University 8-phenyl-isoquinolines and pharmaceutical composition thereof used in the treatment of irritable bowel syndrome
AU2018352695A1 (en) 2017-10-19 2020-05-28 Effector Therapeutics, Inc. Benzimidazole-indole inhibitors of Mnk1 and Mnk2
CN110372584A (zh) * 2019-06-25 2019-10-25 南京普锐达医药科技有限公司 一种2,4-二氯-6-氰基嘧啶的合成方法
IL314405A (en) * 2022-01-18 2024-09-01 Bsense Bio Therapeutics Ltd Substances affecting the potassium channel and the TRPV1 channel and their uses
WO2023147063A2 (en) * 2022-01-28 2023-08-03 Opna Bio SA Compounds and methods for yap/tead modulation and indications therefor
WO2024210578A1 (ko) * 2023-04-05 2024-10-10 주식회사 바오밥에이바이오 헤테로비시클릭 화합물 및 그를 포함하는 약제학적 조성물

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010022055A2 (en) * 2008-08-20 2010-02-25 Amgen Inc. Inhibitors of voltage-gated sodium channels
WO2011103196A1 (en) * 2010-02-17 2011-08-25 Amgen Inc. Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain
WO2011105572A1 (ja) * 2010-02-26 2011-09-01 持田製薬株式会社 新規ヘテロアリール誘導体
WO2011141474A1 (en) * 2010-05-12 2011-11-17 Boehringer Ingelheim International Gmbh Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
WO2012135697A2 (en) * 2011-03-30 2012-10-04 H. Lee Moffitt Cancer Center & Research Institute Inc. Novel rho kinase inhibitors and methods of use

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001526648A (ja) 1997-04-22 2001-12-18 コセンシス・インコーポレイテッド 炭素環及びヘテロ環で置換されたセミカルバゾン及びチオセミカルバゾン、及びその使用
ES2352739T3 (es) 1997-11-21 2011-02-22 Purdue Neuroscience Company 2-aminoacetamidas sustituidas y el uso de las mismas.
US6281211B1 (en) 1999-02-04 2001-08-28 Euro-Celtique S.A. Substituted semicarbazides and the use thereof
ATE467620T1 (de) 1999-03-26 2010-05-15 Euro Celtique Sa Arylsubstituierte pyrazole, imidazole, oxazole, thiazole und pyrrole, sowie deren verwendung
DK1169060T3 (da) 1999-04-09 2006-01-16 Euro Celtique Sa Natriumkanalblokkerpræparater og anvendelse deraf
US7087597B1 (en) * 1999-10-12 2006-08-08 Takeda Pharmaceutical Company Limited Pyrimidine 5-carboxamide compounds, process for producing the same and use thereof
AR029489A1 (es) 2000-03-10 2003-07-02 Euro Celtique Sa Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento
CN1321112C (zh) 2000-03-24 2007-06-13 欧洲凯尔特股份有限公司 作为钠通道阻滞剂的芳基取代的吡唑、三唑和四唑化合物
US6335354B2 (en) 2000-03-31 2002-01-01 Cocensys Inc. Aminopyridines and methods of using thereof
IL159765A0 (en) 2001-07-16 2004-06-20 Euro Celtique Sa Aryl substituted thiazolidinone derivatives and pharmaceutical compositions containing the same
AR037233A1 (es) 2001-09-07 2004-11-03 Euro Celtique Sa Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento
AR036873A1 (es) 2001-09-07 2004-10-13 Euro Celtique Sa Piridinas aril sustituidas a, composiciones farmaceuticas y el uso de las mismas para la preparacion de un medicamento
KR20040099324A (ko) 2002-03-13 2004-11-26 유로-셀티큐 에스.에이. 아릴 치환된 피리미딘 및 이것의 용도
KR20050026031A (ko) 2002-07-31 2005-03-14 유로-셀티큐 에스.에이. 아릴 치환된 벤즈이미다졸 및 나트륨 채널 차단제로서이의 용도
CN1671387A (zh) 2002-07-31 2005-09-21 欧洲凯尔特股份有限公司 芳基取代的乙内酰脲化合物及其作为钠通道阻滞剂的应用
US20040152696A1 (en) 2002-08-01 2004-08-05 Euro-Celtique S.A. 2-substituted bicyclic benzoheterocyclic compounds and their use as sodium channel blockers
WO2005014849A2 (en) 2003-07-03 2005-02-17 Euro-Celtique, S.A. Genes associated with responses to neuropathic pain
JP2008519034A (ja) * 2004-11-03 2008-06-05 バーテックス ファーマシューティカルズ インコーポレイテッド イオンチャネル調節剤としてのピリミジン誘導体および使用方法
WO2007148185A2 (en) * 2006-06-21 2007-12-27 Pfizer Products Inc. Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
EP2225223B1 (de) * 2007-11-22 2017-01-11 Boehringer Ingelheim International GmbH Organische verbindungen
JP5685203B2 (ja) 2009-05-29 2015-03-18 ラクオリア創薬株式会社 カルシウムチャネル遮断薬またはナトリウムチャネル遮断薬としてのアリール置換カルボキサミド誘導体
WO2011158108A2 (en) 2010-06-16 2011-12-22 Purdue Pharma L.P. Aryl substituted indoles and the use thereof
EP2593434A1 (en) 2010-07-16 2013-05-22 Purdue Pharma LP Pyridine compounds as sodium channel blockers
AU2011303597A1 (en) 2010-09-17 2013-04-11 Purdue Pharma L.P. Pyridine compounds and the uses thereof
WO2012046132A1 (en) 2010-10-05 2012-04-12 Purdue Pharma L.P. Quinazoline compounds as sodium channel blockers
KR20130119964A (ko) 2010-12-22 2013-11-01 퍼듀 퍼머 엘피 나트륨 채널 차단제로서의 치환된 피리딘
US9226929B2 (en) 2011-03-02 2016-01-05 Bayer Intellectual Property Gmbh Pharmaceutically active disubstituted triazine derivatives
EP2753606B1 (en) 2011-09-02 2017-07-05 Purdue Pharma LP Pyrimidines as sodium channel blockers
AU2012321111A1 (en) 2011-10-31 2013-05-16 Purdue Pharma L.P. Quaternized amines as sodium channel blockers
US9181185B2 (en) 2011-10-31 2015-11-10 Purdue Pharma L.P. Heteroaryl compounds as sodium channel blockers
US9133131B2 (en) 2011-11-15 2015-09-15 Purdue Pharma L.P. Pyrimidine diol amides as sodium channel blockers
AU2013203824A1 (en) 2012-03-16 2013-10-03 Purdue Pharma L.P. Substituted pyridines and pryimidines as sodium channel blockers
US9714252B2 (en) 2012-12-20 2017-07-25 Purdue Pharma L.P. Cyclic sulfonamides as sodium channel blockers
US9120786B2 (en) 2013-03-04 2015-09-01 Purdue Pharma, L.P. Triazine carboxamides as sodium channel blockers
ES2680246T3 (es) 2013-03-04 2018-09-05 Purdue Pharma Lp Pirimidincarboxamidas como bloqueantes de canal de sodio
CA3082427A1 (en) 2013-03-15 2014-09-25 Purdue Pharma L.P. Carboxamide derivatives and use thereof
US9359330B2 (en) 2013-08-26 2016-06-07 Purdue Pharma L.P. Substituted piperidines as sodium channel blockers
US9828348B2 (en) 2013-11-08 2017-11-28 Purdue Pharma L.P. Benzimidazole derivatives and use thereof
US9340504B2 (en) 2013-11-21 2016-05-17 Purdue Pharma L.P. Pyridine and piperidine derivatives as novel sodium channel blockers
US9695144B2 (en) 2013-12-23 2017-07-04 Purdue Pharma L.P. Dibenzazepine derivatives and use thereof
US10730866B2 (en) 2014-04-07 2020-08-04 Purdue Pharma L.P. Indole derivatives and use thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010022055A2 (en) * 2008-08-20 2010-02-25 Amgen Inc. Inhibitors of voltage-gated sodium channels
WO2011103196A1 (en) * 2010-02-17 2011-08-25 Amgen Inc. Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain
WO2011105572A1 (ja) * 2010-02-26 2011-09-01 持田製薬株式会社 新規ヘテロアリール誘導体
WO2011141474A1 (en) * 2010-05-12 2011-11-17 Boehringer Ingelheim International Gmbh Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
WO2012135697A2 (en) * 2011-03-30 2012-10-04 H. Lee Moffitt Cancer Center & Research Institute Inc. Novel rho kinase inhibitors and methods of use

Also Published As

Publication number Publication date
CA2939501A1 (en) 2015-08-20
WO2015123398A1 (en) 2015-08-20
AU2015217185B2 (en) 2018-04-05
US11401258B2 (en) 2022-08-02
CA2939501C (en) 2020-07-07
EP3105217A4 (en) 2017-08-09
JP2017511794A (ja) 2017-04-27
US20170057942A1 (en) 2017-03-02
CN106103422A (zh) 2016-11-09
JP6556154B2 (ja) 2019-08-07
IL247252A0 (en) 2016-09-29
US10738026B2 (en) 2020-08-11
IL247252B (en) 2020-04-30
EP3105217B1 (en) 2019-05-29
US20200407338A1 (en) 2020-12-31
EP3105217A1 (en) 2016-12-21
AU2015217185A1 (en) 2016-09-01

Similar Documents

Publication Publication Date Title
CN106103422B (zh) 异喹啉衍生物及其用途
CN106103415B (zh) 吲唑和其用途
JP6830498B2 (ja) カルボキサミド誘導体及びその使用
US11834447B2 (en) Indole derivatives and use thereof
JP6526023B2 (ja) ピリジン類及びピリミジン類並びにその使用
JP6422498B2 (ja) アザスピロ［４．５］デカン誘導体及びその使用
US10125113B2 (en) Dibenzazepine derivatives and use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20200918

Termination date: 20210212

CF01 Termination of patent right due to non-payment of annual fee